Navigation Links
InspireMD Announces First Quarter 2012 Financial Results

TEL AVIV, Israel, May 8, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced financial results for the quarter ended March 31st 2012.

Ofir Paz, Co-Founder and CEO of InspireMD, said: "The quarter was marked by continued positive momentum across financial, operational and clinical areas. Demand for MGuard™ increased in the majority of our international markets.  We strengthened our senior management, and  additional positive data on MGuard™ was reported.  We also recently raised gross proceeds of $11 million in a private placement, which strengthened our balance sheet for the global launch of MGuard™."

Eli Bar, Vice President of R&D added: "We continue to make excellent progress in the MASTER trial, which is now more than 85% enrolled. We remain committed to completing enrollment in the second quarter and releasing preliminary top line results in the third quarter of 2012.  A successful outcome in this trial could lead to MGuard™ becoming the standard of care for patients with acute myocardial infarctions."

Financial Highlights

  • Total revenue for the three months ended March 31, 2012 was $1.1 million, compared with approximately $1.7 million during the same period in 2011.
  • The decrease in revenue year over year was mainly attributable to a one time order of approximately $1.2 million by the Company's distributor in India during the first three months of 2011 that the Company did not receive in 2012.
  • Shipments to other countries (excluding India) during the three months ended March 31, 2012 increased by approximately $0.6 million, or 113.9%, compared to the same period in 2011. Sales of MGuard™ increased in the majority of the Company's major markets during the three months ended March 31, 2012, including Mexico, Israel, Germany, Poland and the Netherlands compared to the same period in 2011. 
  • Gross profit in the quarter was $0.6 million, a decrease of 28.3% or approximately $0.2 million, from $0.8 million during the same period in 2011. The gross margin in the quarter increased to 49.6% from 46.7% during the same period in 2011.
  • Total operating expenses were $3.7 million, compared to $2.0 million in the same period of 2011. This increase was mainly driven by share-based compensation of $0.8 million, increased R&D expenditures relating to the MASTER trial and planned FDA trials of $0.8 million, and other expenses of $0.1 million. 
  • Loss from operations in the quarter was $3.1 million, compared to a loss from operations of $1.2 million in the comparable period in 2011.
  • The net loss for the quarter was $3.1 million, or $0.05 per weighted average share, compared to a net loss of $1.9 million in the comparable period in 2011.
  • The Company ended the quarter with cash and cash equivalents of approximately $3.4 million, as compared to $5.1 million as of December 31, 2011.
  • Achievements in 1Q 2012

  • Enrollment continued in the MASTER Trial which is comparing MGuard™ with the standard of care in STEMI patients. As of May 4, 2012, 370 patients (out of 432 planned) were enrolled.
  • Positive clinical results were reported from the MICAMI trial of MGuard™ at the Cardiovascular Research Technologies (CRT) conference in Washington D.C. This randomized controlled trial showed a significant improvement in microvascular reperfusion for MGuard™ vs. bare metal stents.
  • Dr. James Barry was appointed to the Board of Directors as an independent director. Dr. Barry is a former senior executive at Boston Scientific and has a proven track record of bringing high value medical technology products to market.
  • Robert Ratini was appointed as Vice President of Sales and Marketing. Mr. Ratini will develop and lead all global marketing strategies for InspireMD's proprietary stent system technology, MGuard™. 
  • Recent (Post Period) Developments

  • On April 5, 2012, the Company completed a private placement with two institutional investors resulting in gross proceeds (before deducting commissions and expenses) of $11.0 million.
  •  CONSOLIDATED STATEMENTS OF OPERATIONS (1)(U.S. dollars in thousands, except per share data)Three months endedMarch 31,2012



    $1,686Cost of Revenues


    899Gross Profit


    787Operating Expenses:Research and development


    343Selling and marketing


    428General and administrative


    1,186Total operating expenses


    1,957Loss from Operations


    (1,170)Financial (income),expenses net


    715Loss before tax expenses


    (1,885)Tax Expenses


    10Net Loss


    $(1,895)Net loss per share - basic and diluted


    $(0.04)Weighted average number of shares of common stock used in computing net loss
    per share - basic and diluted


    50,798,900 CONSOLIDATED BALANCE SHEETS (1)(U.S. dollars in thousands)March 31,

    December 31,2012

    2011ASSETSCurrent Assets:Cash and cash equivalents


    $5,094Restricted cash


    91Accounts receivable:Trade




    118Prepaid expenses


    72Inventory:On hand


    2,061On consignment


    110Total current assets


    9,830Property, plant and equipment, net of accumulated depreciation and amortization


    420Other non-current assets:Funds in respect of employees rights upon retirement


    215Deferred issuance costs

    25Total other non-current assets


    215Total assets


    $10,465 March 31,

    December 31,2012

    2011LIABILITIES AND EQUITYCurrent liabilities:Current maturities of long-term loans


    $94Accounts payable and accruals:Trade




    2,217Advanced payment from customers


    316Deferred revenues

    25Total current liabilities


    3,441Long-term liabilityLiability for employees rights upon retirement


    270Total long-term liabilities


    270Commitments and contingent liabilities -Total liabilities


    3,711Equity:Common stock, par value $0.0001 per share; 125,000,000 shares authorized;
    68,178,946 shares issued and outstanding at March 31, 2012
    and December 31, 2011.


    7Additional paid-in capital


    43,388Accumulated deficit


    (36,641)Total equity


    6,754Total liabilities and equity 


    $10,465(1) All 2012 financial information is derived from the Company's 2012 unaudited financial statements and all 2011 financial information is derived from the Company's 2011 audited financial statements, as disclosed in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission.

    About MGuard Coronary StentMGuard™ presents a novel combination of a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that wraps the stent. The MGuard™ stent provides outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).

    MGuard™ is currently being investigated in the multi-center international MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial. This study has been designed to evaluate the MGuard™ stent compared to commercially-approved BMS or DES products in STEMI patients undergoing primary angioplasty. Preliminary top line results are expected in the third quarter of 2012. Plans for a registration study in the US are also at an advanced stage.

    About InspireMD, Inc.InspireMD is a medical device company focused on the development and commercialization of its proprietary stent system technology, MGuard. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".

    Forward-looking Statements: This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Registration Statement on Form S-1 filed with the SEC on April 25, 2012. Investors and security holders are urged to read these documents free of charge on the SEC's web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Investor Contact:
    Mike Rice
    Office Phone: (646) 597-6979

    Corporate Contact:
    Jonina Ohayon
    Marketing Director


    SOURCE InspireMD, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
    2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
    3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
    4. InspireMD Boosts MGuard Production Capacity
    5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
    6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
    7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
    8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
    9. InspireMD Announces Year-to-Date 2011 Progress
    10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
    11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
    Post Your Comments:
    (Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
    (Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
    (Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
    (Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
    (Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
    Breaking Medicine News(10 mins):